logo Ampleia blanc

LET'S MEET with
OUR TEAM

OUR TEAM

Photo de Alexandre LEMOALLE

Alexandre
Lemoalle

president

Alexandre brings to Ampleia three decades of experience across pharma, biotech and investment banking.

Alexandre is Head of Strategic Projects at Genethon and Managing Partner at Finpact, a French boutique dedicated to fund raising in healthcare and planet care.

He was Head of Business Development and Partnerships at Genethon where we contributed to the execution of strategic deals.

Before joining Genethon, Alexandre spent 20 years at Sanofi including ten years in finance across in Europe and Asia and ten years general management and executive positions. As part of his time at Sanofi, he led the group in 25 acquisitions including Genzyme in 2011 and was CFO Asia, member of the Finance ExCom of Sanofi.

Alexandre is graduated from Institut Supérieur de Gestion (ISG) business school.

Photo de Pierre-Albert COLCOMB

Pierre-Albert
Colcomb

chief operating officer

Pierre-Albert joined Ampleia at inception in 2023, bringing a decade of experience in biotech and finance.

Before joining Ampleia, Pierre-Albert was Business Development Director at Genethon, a leading gene therapy developer where he contributed to crafting deals with key players in rare diseases and gene therapy including Sarepta, Spark (acq. by Roche) or AveXis (acq. by Novartis). He was instrumental in the creation of several biotechs, including Atamyo Therapeutics. As part of his position, Pierre-Albert was also responsible for the business development activities of I-Stem, a research center dedicated to cell culture and differentiation. He negotiated several deals in the field of drug screening and cell therapy, including a strategic partnership with Urgo Group in skin diseases.
Pierre-Albert started his career as an analyst at Clipperton Finance, a technology-focused investment bank.

He graduated from ESPCI Paris and ESSEC Business School.
Photo de Jean-francois BRIAND

Jean-Francois
Briand

Permanent member of the Investment Committee

Jean-Francois Briand is Operations and Innovation Director at AFM-Telethon.

He joined the association in 2011 and held several leading positions in the identification and selection of world-class projects in rare diseases. His team is financing and managing the exploitation of 350 research projects across international academic institutions and biotechs with the ambition to further push boundaries in disease understanding and new technologies emergence for rare disorders.

Jean-Francois started his career as scientist at the Center for Atomic Energy before joining biotech industry where he was managing molecular biology departments and developing various research projects in recombinant protein production, infectious diseases and oncology programs development.

Jean-Francois holds a PhD in microbiology and virology from Sorbonne University.

Photo de Ralph LAUFER

Ralph
Laufer

Permanent member of the Investment Committee

Ralph brings to Ampleia his long and successful experience in pushing drugs from discovery to commercialization. 

Ralph is CSO at Neuvasq, a privately held research company focusing on the discovery and development of therapies to safeguard or rebuild CNS barriers. Prior to that, Ralph was CSO at Lysogene, a clinical-stage listed company developing gene therapies for lysosomal storage disorders. Before joining Lysogene, Ralph was Senior Vice President at Teva, in charge of small molecule Discovery and Product Development. Through his leadership, his team contributed to FDA approval of three drugs for neurological diseases and the clinical development of several programs covering a wide range of therapeutic areas, incl. neurological, inflammatory, respiratory and oncological diseases. He joined Teva from IRBM, where he was the Scientific Director. Prior to that, he was Head of Pharmacology at IRBM-Merck Research Laboratories Rome. Over his career, Ralph contributed to the discovery and/or development of several commercialized products, including Austedo® (for tardive dyskinesia and Huntington’s disease chorea) and Isentress® (for HIV-AIDS).

Ralph is board member at EG427 and scientific advisor of several biotechs, disease foundations, and academic institutions. He holds a Ph.D in biochemistry from The Hebrew University of Jerusalem.

Photo de Serge BRAUN

Serge
Braun

Permanent member of the Investment Committee

Our Partners

logo afm telethon

Created in 1958 in France, AFM-Telethon is an association of patients dedicated to supporting patients and developing treatments for rare diseases. All along its history, AFM-Telethon has taken a pioneering role financing disruptive research and creating its own laboratories to find treatments for these neglected diseases, and bring them to patients. Within 30 years of research, AFM-Telethon has invested €1.7b to design treatments and bring them to patient’s bedside. Supported by a wide and international network of scientists, developers and clinicians, the technologies initiated by AFM-Telethon are now becoming real therapeutic options for rare diseases patients and give hope to millions of patient affected by rare and non-rare indications.